Vara is dedicated to making data-driven breast cancer screening more accessible and reliable globally. The company combines state-of-the-art AI technology with the expertise of leading physicians to deliver impactful, clinically backed breast cancer screening solutions aimed at early detection for better health outcomes.

Vara's mission is to detect every deadly breast cancer early, improving outcomes for everyone, everywhere. The company builds an AI-powered platform supporting the entire breast cancer screening pathway, involving all stakeholders from patients to radiologists and healthcare professionals. Vara focuses on increasing accessibility, affordability, and accuracy of breast cancer screening using AI.

Founded as a spin-off from Merantix Venture Studio in 2018, Vara quickly gathered development partners in German screening centers to co-create their AI screening platform. They obtained CE class IIb medical certification and have since expanded internationally, launching screening units and conducting large-scale clinical studies proving the effectiveness of their technology.

Vara fosters a culture of ownership, accountability, transparency, diversity, and continuous learning. They promote flexible working conditions, career development, and competitive salaries. Employees are seen as integral to the company's success in transforming breast cancer screening globally.

The company is led by CEO Jonas Muff and supported by a team of experienced leaders and advisors with backgrounds in medical imaging, healthcare, and AI. They also have strong investor backing including OMERS Ventures and others.